The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 349:2449-2451 December 18, 2003 Number 25
NextNext

Medical Management of Benign Prostatic Hyperplasia — Are Two Drugs Better Than One?
E. Darracott Vaughan, Jr., M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by McConnell, J. D.
-PubMed Citation
The prostate is a complex organ composed of epithelial cells and fibromuscular stroma. Benign prostatic hyperplasia is a true hyperplastic process, with an increase in the number of cells arising initially in the transition zone of the gland. Complex stromal–epithelial interactions lead to benign prostatic hyperplasia in 50 percent of men by the age of 50 years. This process requires testicular androgens and progresses with age. Aging is accompanied by an increase in symptoms of bladder obstruction or irritation attributable to benign prostatic hyperplasia. A prospective study showed that 24 percent of men with moderate symptoms of benign prostatic hyperplasia . . . [Full Text of this Article]


Source Information

From the Department of Urology, Weill Medical College of Cornell University, New York.


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.